SCHEMBL4677145

SCHEMBL4677145

Cc1ccc(Cc2nc(C(=O)C=C(O)c3nn[nH]n3)cs2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 1/20 0.40
HDAC8 Q9BY41 1/20 0.40
HDAC6 Q9UBN7 1/20 0.40
LMNA P02545 6/20 0.38
SMN1; SMN2 Q16637 5/20 0.38
MAPT P10636 5/20 0.38
ALDH1A1 P00352 4/20 0.38
NPC1 O15118 2/20 0.38
GAA P10253 2/20 0.38
CYP1A2 P05177 2/20 0.38
CYP3A4 P08684 2/20 0.38
CYP2C9 P11712 2/20 0.38
CYP2C19 P33261 2/20 0.38
ALOX12 P18054 1/20 0.38
POLB P06746 1/20 0.38
RAB9A P51151 3/20 0.36
KMT2A Q03164 3/20 0.36
L3MBTL1 Q9Y468 2/20 0.36
MEN1 O00255 1/20 0.36
DPP4 P27487 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4675054 0.90 HDAC1 (0.50) HDAC1HDAC8HDAC6LMNASMN1; SMN2
SCHEMBL4679021 0.90 HDAC1 (0.38) HDAC1HDAC8HDAC6LMNASMN1; SMN2
SCHEMBL4676399 0.90 RAB9A (0.47) HDAC1HDAC8HDAC6LMNASMN1; SMN2
SCHEMBL4676864 0.90 HDAC1 (0.40) HDAC1HDAC8HDAC6LMNASMN1; SMN2
SCHEMBL4674861 0.89 LMNA (0.52) HDAC1HDAC8HDAC6LMNASMN1; SMN2
SCHEMBL4674215 0.88 HDAC1 (0.40) HDAC1HDAC8HDAC6LMNASMN1; SMN2
SCHEMBL4671891 0.83 LMNA (0.40) HDAC1HDAC8HDAC6LMNASMN1; SMN2
SCHEMBL4676190 0.82 RAB9A (0.41) HDAC1HDAC8HDAC6LMNASMN1; SMN2
SCHEMBL4676673 0.81 PTGER4 (0.33)
SCHEMBL4679320 0.81 AOC3 (0.32) SMN1; SMN2MAPTALDH1A1NPC1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
CN-1335834-A Aromatic heterocyclic compounds having HIV integrase inhibitory activity SHIONOGI & CO (JP) 2002-02-13 CN disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 HDAC1 250/4885HDAC8 167/4885HDAC6 1000/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.